Nath Bio-Genes (India) share news, announcements and annual reports
NSE: NATHBIOGENBSE: 537291Agricultural Food & other ProductsSmall Cap
Nath Bio-Genes (India) Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 2014
Last close ₹131.01down ₹1.37 (1.03%)BSE ₹131.50
Share price at the NSE close on 30 Oct 2026. Previous close ₹132.38.
30 Oct: open ₹132.05, high ₹135.95, low ₹130.52
52-week range of traded prices to 30 Oct 2026
₹126.15Low, 30 Mar 2026₹204.00High, 30 Apr 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹249 Cr2,134th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 6.80
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 8.47
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.37
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.53%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.5%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹7.21 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 4.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,41466.2% delivered
Nath Bio-Genes (India) share news and announcements
336 announcements, routine notices left out, newest first. Page 5 of 7.
Oct 2019
24 Oct · Board meeting
Aug 2019
5 Aug · Results
5 Aug · Analysts
Jul 2019
24 Jul · Updates
22 Jul · Board meeting
Jun 2019
28 Jun · Related Party Transactions
May 2019
31 May · Analysts
30 May · Results
30 May · Board meeting
Apr 2019
22 Apr · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 11-Apr-2019, regarding retirement. On basis of above you are required to clarify following -1. Date of appointment/cessation (as applicable) & term of appointment.The response of the Company is awaited.11 Apr
Feb 2019
2 Feb · Board meeting
2 Feb · Results
Jan 2019
24 Jan · Board meeting
Nov 2018
21 Nov · Analysts
20 Nov · Analysts
19 Nov · Analysts
Oct 2018
31 Oct · Results
22 Oct · Board meeting
Sep 2018
26 Sep · Analysts
21 Sep · Analysts
4 Sep · Name Change
Aug 2018
1 Aug · Change in Company Secretary/Compliance Officer
1 Aug · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 31-Jul-2018, regarding " Nath Bio-Genes (India) Limited has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2018.". On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment); The response of the Company is awaited.
Jul 2018
31 Jul · Board meeting
31 Jul · Results
20 Jul · Board meeting
4 Jul · Updates
Jun 2018
27 Jun · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to announcement dated 27-Jun-2018, regarding " Nath Bio-Genes (India) Limited has informed the Exchange regarding Management Enhancement.". On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment; The response of the Company is awaited.27 Jun · Management
21 Jun · Rating
1 Jun · Legal
Exchange has sought clarification from Nath Bio-Genes (India) Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted -2. Standalone Reconciliation of Equity not submitted The response of the Company is awaited.1 Jun · Results
May 2018